Sign in to view content

SCORE2 Month 6 to Month 12 Results: 12 Month Outcomes of Treatment Change among Poor Responders at Month 6

Michael S. Ip, MD

Video
Published 2018

Related

Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): The Phase 3 PANORAMA Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2018
Effect of Fluocinolone Acetonide 0.2µg/day (ILUVIEN®) Implant on the Decision to Drive in Patients With Differential Control of DME
Seenu M. Hariprasad, MD
On Demand Cases, Courses, and Papers
2018
Advanced Image Analysis and Machine-Learning Assessment of the Impact of Aflibercept on Anatomic Feature and Flow Dynamics in the PERMEATE Study
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2018

Category: Retinal Vascular Disease

See more